West Michigan Advisors LLC bought a new position in shares of Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 389,710 shares of the company’s stock, valued at approximately $47,000.
Separately, Geode Capital Management LLC grew its holdings in shares of Zomedica by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 9,929,716 shares of the company’s stock valued at $1,363,000 after purchasing an additional 321,395 shares during the last quarter. 8.95% of the stock is currently owned by institutional investors and hedge funds.
Zomedica Price Performance
Shares of ZOM opened at $0.11 on Friday. Zomedica Corp. has a 52 week low of $0.09 and a 52 week high of $0.20. The firm has a market capitalization of $106.23 million, a PE ratio of -1.81 and a beta of 1.03.
Wall Street Analyst Weigh In
Get Our Latest Analysis on ZOM
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Read More
- Five stocks we like better than Zomedica
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- How Investors Can Find the Best Cheap Dividend Stocks
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- MarketBeat Week in Review – 02/24 – 02/28
Want to see what other hedge funds are holding ZOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report).
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.